By Aaron Krol
March 28, 2016 | This month, Veritas Genetics, a DNA testing company based in Cambridge, Mass., began taking orders for its $999 myGenome service. Customers will mail saliva samples to the Veritas lab, where their DNA will be extracted and their entire genomes sequenced. The service includes a report on any genetic variants Veritas finds that could affect customers’ risks of developing serious diseases, or have other implications for their lifestyle and health.
It’s very similar to the product that the FDA forced 23andMe to stop selling in 2013. 23andMe, however, only scanned the genome for select variants at certain hotspots. (It still does, although these days the FDA only lets the company report on the health implications of a small handful of those variants.) The myGenome service goes much further.
“We’re pushing the boundaries,” says Preston Estep, Veritas’ Chief Scientific Officer. “We’re definitely providing more value than anybody else.”
Read the whole story at Bio-IT World.